Management of Accidental Quetiapine Overdose
Since the patient is asymptomatic 6 days after receiving double the prescribed dose (1600 mg instead of 800 mg daily) for only 2 days, no specific intervention is required beyond continuing the original prescribed dose of 800 mg daily and monitoring for any delayed effects.
Clinical Reasoning
The patient received 1600 mg daily for 2 days (total excess exposure of 1600 mg over the intended dose), which occurred 6 days ago. The key clinical considerations are:
Overdose Context and Risk Assessment
The FDA label for quetiapine 1 reports survival in acute overdoses up to 30 grams, with death reported at 13.6 grams in clinical trials. The patient's total excess exposure (1600 mg over 2 days) is substantially below concerning thresholds. Research on quetiapine overdose demonstrates:
- Doses of 2000-3000 mg typically cause CNS depression, tachycardia, and QTc prolongation that resolves within 18-42 hours 2, 3, 4
- Severe toxicity (requiring intubation) generally occurs with ingestions >10,000 mg 5
- Clinical effects peak within 2-4 hours and resolve within 16-48 hours 3, 4, 5
Time Course and Current Status
Six days have elapsed since the last excessive dose. All significant quetiapine toxicity manifests acutely:
- Peak effects occur 2-4 hours post-ingestion 3, 4
- QTc prolongation resolves by 18-42 hours 2, 4
- Tachycardia resolves by 40-48 hours 4, 5
- CNS depression improves within 16 hours 4, 5
The patient being asymptomatic at 6 days post-exposure effectively rules out any ongoing toxicity.
Pharmacokinetic Considerations
Quetiapine has a half-life of approximately 6-7 hours 6. After 6 days (>20 half-lives), any excess drug from the overdose has been completely eliminated. Research on missed doses demonstrates that quetiapine levels return to steady-state rapidly after dosing irregularities 7.
Specific Management Steps
Immediate Actions
- Resume the prescribed dose of 800 mg daily without any dose adjustment
- Document the medication error in the medical record
- Implement systems to prevent recurrence (pharmacy double-check, patient education)
Monitoring Requirements
While no acute intervention is needed, prudent monitoring includes:
- Assess for any delayed symptoms: somnolence, dizziness, tachycardia, orthostatic hypotension 1
- No ECG required at this time point, as QTc prolongation from quetiapine overdose resolves within 18-42 hours 2, 4
- No laboratory testing indicated unless symptoms develop
Patient Education
Inform the patient:
- The error has been identified and corrected
- No harm is expected given the asymptomatic status at 6 days
- To report any new symptoms (excessive drowsiness, dizziness, rapid heartbeat)
- The importance of medication reconciliation at each visit
Important Caveats
Cardiac considerations: While quetiapine causes dose-dependent QTc prolongation 8, 9, the 2023 Canadian Cardiovascular Society guidelines 10 note that risk increases significantly when QTc exceeds 500 ms or increases by >60-70 ms. The modest dose excess (doubling from 800 to 1600 mg) for only 2 days, now 6 days past, poses negligible ongoing cardiac risk.
Chronic dosing context: The patient's baseline dose of 800 mg daily is already at the FDA-approved maximum 1. However, research demonstrates quetiapine can be safely administered at doses up to 2000 mg/day with therapeutic drug monitoring 11. The brief 2-day exposure to 1600 mg does not constitute chronic high-dose therapy.
No dose adjustment needed: Unlike scenarios requiring dose titration after missed doses 7, this situation involves returning to the established therapeutic dose after brief excess exposure. The patient's steady-state has been re-established over the past 6 days.